Sinobios: The first subject in China's pivotal Phase III clinical trial of IBI3003 for the treatment of relapsed or refractory multiple myeloma in the fourth or fifth line has been dosed.

On June 22nd, Sinopharm Biological Pharmaceutical Group announced that the first subject in China's pivotal Phase III clinical trial for the innovative anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003, developed independently by the company, has been dosed for the treatment of relapsed/refractory multiple myeloma in the second to fifth line.